Antiviral Drugs - Uruguay

Uruguay

In Uruguay, the revenue in the Antiviral Drugs market is estimated to reach US$21.43m in 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 1.74%, leading to a market volume of US$23.36m by 2029.
When compared globally, United States is projected to generate the highest revenue of US$30,640.00m in 2024.
Uruguay's antiviral drug market is experiencing a surge in demand due to increased awareness and government initiatives.

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

Antiviral drugs have been in high demand worldwide since the outbreak of COVID-19. Uruguay is no exception to this trend.

Customer preferences: Uruguayan customers are becoming more conscious of their health and are prioritizing the prevention of diseases. This has led to an increased demand for antiviral drugs in the country. Customers are also looking for affordable and accessible options, which has led to a rise in generic antiviral drugs in the market.

Trends in the market: The antiviral drugs market in Uruguay is expected to grow steadily in the coming years due to the increasing prevalence of viral diseases. The COVID-19 pandemic has accelerated this trend, leading to a surge in demand for antiviral drugs. The market is also witnessing a shift towards more advanced antiviral drug therapies, which are more effective and have fewer side effects.

Local special circumstances: Uruguay has a strong public healthcare system that provides free healthcare to all its citizens. This has led to a high demand for affordable antiviral drugs in the country. The government has also been proactive in promoting public health awareness, which has led to an increased demand for preventive measures such as antiviral drugs.

Underlying macroeconomic factors: Uruguay has a stable economy with a strong focus on healthcare. The government has been investing heavily in the healthcare sector, which has led to an increase in the availability of antiviral drugs in the country. The country's aging population is also a key driver of the antiviral drugs market, as older adults are more susceptible to viral diseases. The increasing prevalence of viral diseases in the region is also expected to drive the growth of the antiviral drugs market in Uruguay.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.